Skip to content

Mechanisms and Clinical Translation of the PER2/HIF-1a–BMAL1/HSD17B13 Axis in Time Rhythm-Dependent Hepatic Protection from Remote Ischemic Conditioning

Mechanisms and Clinical Translation of the PER2/HIF-1a–BMAL1/HSD17B13 Axis in Time Rhythm-Dependent Hepatic Protection from Remote Ischemic Conditioning

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121470
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic resection of liver tumor

Interventions

Control group :Remote Ischemic Conditioning (at the time point of 30 min after the start of the surgery, 9:00-10:00 am on postoperative day 1 and day 2): Three cycles (30 minutes), each consisting of
Rhythm group:Remote Ischemic Conditioning (7:00-8:00 am on the day of surgery, postoperative day 1, and postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflati

Sponsors

Yongchuan Hospital Affiliated to Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective partial liver resection; 2. American Society of Anesthesiology (ASA) classification levels II-III; 3. Age between 25 and 75 years old; 4. New York Heart Association (NYHA) classification levels I-III.

Exclusion criteria

Exclusion criteria: 1. Patients with limb impairments or those suffering from peripheral vascular diseases that affect upper limb function; 2. Patients with a history of neurological, immune system, or mental disorders; 3. Patients who have previously undergone liver resection, have recent significant organ diseases, or have undergone surgical treatment; 4. Patients who have recently used anti-inflammatory analgesics, anticoagulants, hormone drugs, immunosuppressants, ATP-sensitive K-channel blockers (KATP); 5. Patients with severe preoperative renal insufficiency (serum creatinine > 442 umol/L, with or without serum potassium > 6.5 mmol/L, or if the clinician deems it necessary for renal replacement therapy), or liver insufficiency (Child-Pugh grade C); 6. Patients and/or their family members refuse to participate in this project.

Design outcomes

Primary

MeasureTime frame
Glutamic-pyruvic transaminase, ALT;Operation time, blood loss and other surgical indicators;

Secondary

MeasureTime frame
Glutamic oxalacetic transaminase, AST;leukocyte, WBC;Neutrophil granulocyte percentage;Tumor necrosis factor-a, TNF-a;Per2;Hypoxia inducible factor-1 alpha, HIF-1a;Intestinal fatty acid-binding protein, I-FABP;Time to gastrointestinal tolerance;Prolonged postoperative ileus;Postoperative duration of hospital stay;Postoperative complications;

Countries

China

Contacts

Public ContactChun Tian

Yongchuan Hospital Affiliated to Chongqing Medical University

Tianchun314@163.com+86 157 2305 9158

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026